Anthracyclines (doxorubicin, epirubicin)
A family of red chemotherapy drugs derived from a soil bacterium that damage cancer DNA. Cornerstones of breast cancer, lymphoma, leukaemia and sarcoma treatment, but they weaken the heart in a dose-dependent way, so there is a lifetime limit.
Doxorubicin, epirubicin, daunorubicin and idarubicin intercalate DNA and poison topoisomerase II. They anchor AC/EC in breast cancer, CHOP in lymphoma, 7+3 in AML and doxorubicin-ifosfamide in sarcoma. Cumulative doses above about 450 mg/m² doxorubicin cause cardiomyopathy, and even lower doses matter in children and with trastuzumab, which motivates anthracycline-free regimens (TCHP, docetaxel-cyclophosphamide), dexrazoxane, liposomal formulations and cardiac surveillance. They also cause alopecia, myelosuppression, and secondary leukaemia (topoisomerase-related, 1-2%), and as ADC payloads they are being revisited.
Pages like this
not linked directly; found by shared links- PairingCaution: cumulative anthracycline dose and the heart
Shares Cardio-oncology, Doxorubicin, Sarcomas (soft tissue, bone, GIST), Diffuse large B-cell lymphoma.
- TermImmune-related myocarditis
Shares Cardiotoxicity (LVEF decline, cardiomyopathy), Cardio-oncology.
- TermLate effects and survivorship toxicity
Shares Secondary malignancy (therapy-related cancer), Cardiotoxicity (LVEF decline, cardiomyopathy).
- TrialANNOUNCE
- InstitutionHamad Medical Corporation / National Center for Cancer Care and Research
Shares Acute myeloid leukaemia, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer.
- TermHypomethylating agents (azacitidine, decitabine)
- TermABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)
Shares Secondary malignancy (therapy-related cancer), Doxorubicin.
- ProductEribulin
Shares Cytotoxic chemotherapy, Sarcomas (soft tissue, bone, GIST), HR-positive / HER2-negative breast cancer.